Paper35280262
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
Hauser RA and 11 others. Front Neurol, 2022. Cited by 14 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. Papers, record 35280262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35280262
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25,069,517 | Deuterated drugs: where are we now? | Expert Opin Ther Pat | 2014 | https://conductscience.org/library/papers/25069517 | PubMed |
| 2 | 31,296,586 | Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. | J Neurol Neurosurg Psychiatry | 2019 | https://conductscience.org/library/papers/31296586 | PubMed |
| 3 | 2,716,220 | Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study. | Keio J Med | 1989 | https://conductscience.org/library/papers/2716220 | PubMed |
| 4 | 30,027,457 | Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. | Neurol Ther | 2018 | https://conductscience.org/library/papers/30027457 | PubMed |
| 5 | 21,131,613 | Spectrum of tardive syndromes: clinical recognition and management. | Postgrad Med J | 2011 | https://conductscience.org/library/papers/21131613 | PubMed |
| 6 | 25,556,809 | Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. | Psychiatry Clin Neurosci | 2015 | https://conductscience.org/library/papers/25556809 | PubMed |
| 7 | 32,720,245 | Management of Tardive Syndrome: Medications and Surgical Treatments. | Neurotherapeutics | 2020 | https://conductscience.org/library/papers/32720245 | PubMed |
| 8 | 29,454,494 | Historical perspectives on tardive dyskinesia. | J Neurol Sci | 2018 | https://conductscience.org/library/papers/29454494 | PubMed |
| 9 | 31,435,866 | Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. | Qual Life Res | 2019 | https://conductscience.org/library/papers/31435866 | PubMed |
| 10 | 24,262,160 | Tardive dyskinesia syndromes: current concepts. | Parkinsonism Relat Disord | 2014 | https://conductscience.org/library/papers/24262160 | PubMed |
| 11 | 1,979,705 | Tardive dyskinesia. | West J Med | 1990 | https://conductscience.org/library/papers/1979705 | PubMed |
| 12 | 20,156,410 | Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. | J Clin Psychiatry | 2010 | https://conductscience.org/library/papers/20156410 | PubMed |
| 13 | 29,433,808 | VMAT2 inhibitors for the treatment of tardive dyskinesia. | J Neurol Sci | 2018 | https://conductscience.org/library/papers/29433808 | PubMed |
| 14 | 32,454,050 | VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. | Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32454050 | PubMed |
| 15 | 30,306,450 | VMAT2 Inhibitors in Neuropsychiatric Disorders. | CNS Drugs | 2018 | https://conductscience.org/library/papers/30306450 | PubMed |
| 16 | 20,869,622 | Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. | Am J Geriatr Pharmacother | 2010 | https://conductscience.org/library/papers/20869622 | PubMed |
| 17 | 28,446,646 | Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. | Neurology | 2017 | https://conductscience.org/library/papers/28446646 | PubMed |
| 18 | 28,146,614 | Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. | J Clin Psychiatry | 2017 | https://conductscience.org/library/papers/28146614 | PubMed |
| 19 | 19,011,586 | Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics. | Psychiatr Danub | 2008 | https://conductscience.org/library/papers/19011586 | PubMed |
| 20 | 10,770,457 | Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. | J Clin Psychopharmacol | 2000 | https://conductscience.org/library/papers/10770457 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,682,903 | Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes. | J Cent Nerv Syst Dis | 2026 | https://conductscience.org/library/papers/42682903 | PubMed |
| 42,487,657 | Tardive Dyskinesia Induced by Long-Acting Injectable Paliperidone Palmitate Once Every 3 Months in a Patient With Schizophrenia: A Case Report and Literature Review. | Clin Case Rep | 2026 | https://conductscience.org/library/papers/42487657 | PubMed |
| 41,981,317 | Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis. | Eur J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/41981317 | PubMed |
| 41,122,869 | VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review. | CNS Spectr | 2025 | https://conductscience.org/library/papers/41122869 | PubMed |
| 39,985,106 | Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database. | BMC Pharmacol Toxicol | 2025 | https://conductscience.org/library/papers/39985106 | PubMed |
| 39,935,362 | From assessment to intervention: evidence-based approaches in tardive dyskinesia. | CNS Spectr | 2025 | https://conductscience.org/library/papers/39935362 | PubMed |
| 39,825,184 | Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. | CNS Drugs | 2025 | https://conductscience.org/library/papers/39825184 | PubMed |
| 38,969,949 | Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38969949 | PubMed |
| 38,557,959 | Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. | Neurol Ther | 2024 | https://conductscience.org/library/papers/38557959 | PubMed |
| 38,131,057 | Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. | Ment Health Clin | 2023 | https://conductscience.org/library/papers/38131057 | PubMed |
| 37,277,503 | Deuterium in drug discovery: progress, opportunities and challenges. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/37277503 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP2D6 | 1,565 | PubTator's text mining | https://conductscience.org/library/genes/1565 | NCBI Gene |
| SLC18A2 | 6,571 | PubTator's text mining | https://conductscience.org/library/genes/6571 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35280262
GET https://conductscience.org/api/papers/v1/35280262/references?page=2